Clinical trials: Carcinoma Breast
Breast Cancer
Efficacy Verification in Early Diagnosis and Management of Lymphedema Through Home Body Water Analyzer
Breast cancer is the second most common cancer in women. One in five women who have been treated for breast cancer develop lymphedema. Lymphedema is a very common result of breast cancer and its treatment.
- Trial name
- NCT06580743
- Testing
- No intervention
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of Minnesota
Breast Cancer Lymphedema, Secondary Lymphedema
Lymphaticovenous Anastomosis as Treatment for Lymphedema
The primary aim of this study is to investigate and test whether the use of combined indocyanine green (ICG) lymphography and ultra high frequency ultrasonography can correctly identify lymphatic vessels and venoles in close…
- Conditions
- Breast Cancer Lymphedema, Secondary Lymphedema, Iatrogenic Lymphedema, Lymphedema
- Trial name
- NCT05441943
- Testing
- Lymphovenous anastomosis
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- Odense University Hospital
Fear, Anxiety
The Effect of 360° Virtual Reality Movies on Fear and Anxiety
To assess the effect of web-based 360° Virtual Reality movies on fear and anxiety, The investigators would like to assess the patient-perceived level of fear and anxiety quantitatively, making use of several questionnaires.
- Conditions
- Fear, Anxiety, Breast Cancer, Lung Cancer
- Trial name
- ENGAGE (NCT06199050)
- Testing
- Questionnaire: SPIRIT, Questionnaire: HADS, Questionnaire: QSC-R23
- Where
- Netherlands
- Volunteers
- 292 people
- Sponsor
- Maastricht Radiation Oncology
Breast Cancer
Biological Matrices Versus Synthetic Meshes
In this feasibility study, 60 women undergoing reconstruction will be randomly allocated to receive biological or synthetic mesh and followed for 6 months.
- Trial name
- BIOSYM (NCT05449691)
- Testing
- One-stage immediate breast reconstruction
- Where
- 5 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- University Hospitals of Derby and Burton NHS Foundation Trust
Radiotherapy Side Effect, Locoregional Recurrence
RCT Comparing 2 Radiotherapy HypoFractionation Schedules In Breast Cancer Patients
This is a prospective randomized Phase III trial to assess efficiency of two post mastectomy hypofractionation schedules (40 Gy /15 fx / 3 weeks, 5 days per week VS 28.5 Gy delivered in 5 once-weekly fractions of 5.7 Gy each…
- Trial name
- Breastcancer (NCT04550910)
- Testing
- Hypofractionation Schedules for Breast Cancer patients after mastecomy
- Where
- Egypt
- Volunteers
- 166 people
- Sponsor
- National Cancer Institute, Egypt
Breast Cancer Metastatic, Treatment Efficacy
A ReaL World Study of DS-8201
A ReaL world study of DS-8201
- Trial name
- EXPLORE (NCT06945224)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Fudan University
Breast Cancer
A Master Protocol Empowering Mechanobiology Translation Research in Breast Cancer
METAMECH is a master observational protocol designed to empower a bi-directional collaboration between basic and clinical research, an essential prerequisite to feed and implement precision oncology.
- Trial name
- METAMECH (NCT04625023)
- Testing
- Observational
- Where
- 10 sites in Italy
- Volunteers
- 1,500 people
- Sponsor
- IFOM ETS - The AIRC Institute of Molecular Oncology
Breast Cancer, Metastasis, Neoplasm
Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer (MBC)
The primary objective of this study is to evaluate the efficacy and tolerability of sequential use of vinorelbine and capecitabine as first line therapy in patients with MBC.
- Trial name
- NCT00629148
- Testing
- Vinorelbine and Capecitabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Sarcopenia, Paclitaxel Induced Neuropathy
Sarcopenia and Paclitaxel-Induced Neuropathy in Early Stage Breast Cancer (Neuro-Sarc)
This prospective observational study aims to investigate the relationship between sarcopenia and the development of paclitaxel-induced peripheral neuropathy in patients with early-stage breast cancer.
- Conditions
- Sarcopenia, Paclitaxel Induced Neuropathy, Breast Carcinoma
- Trial name
- Neuro-Sarc (NCT06996548)
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Gazi University
Breast Cancer, Adherence, Medication
Adherence and Safety of Ribociclib Plus Aromatase Inhibitors in Patients With Early Stage, HR+ and HER2- Breast Cancer
Breast cancer is the most common malignancy in women, with HR+/HER2- early breast cancer accounting for approximately 70% of cases.
- Trial name
- riboADHERE (NCT07630948)
- Testing
- Adherence package consisting of additional education and adherence reminders
- Where
- Slovenia
- Volunteers
- 90 people
- Sponsor
- Institute of Oncology Ljubljana
Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
Patients with advanced HER2+ breast cancer on maintenance trastuzumab/pertuzumab or T-DM1 with 1st or 2nd intracranial disease event (brain metastases) and stable extracranial disease will be enrolled.
- Conditions
- Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer
- Trial name
- BRIDGET (NCT05323955)
- Testing
- Trastuzumab, Trastuzumab Emtansine (T-DM1), Pertuzumab
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Carey Anders, M.D.
Non Metastatic Breast Cancer
Biological Response to Tamoxifen (TAM) in Patients With Breast Cancer Non Metastatic RH+
The biological response to treatment with tamoxifen in the preoperative situation is studying in this protocol. This study will enrolls patients with non-metastatic breast cancer HR +.
- Trial name
- TAM (NCT01220076)
- Testing
- tamoxifen
- Where
- 3 sites in France
- Volunteers
- 140 people
- Sponsor
- Institut Cancerologie de l'Ouest
Early-stage Breast Cancer, Carbohydrate Engorgement
Breast Cancer Diet Intervention Study
The investigators have already proven that Mitotic Activity Index (MAI)is the most robust measure of proliferation in breast cancer tissue.
- Conditions
- Early-stage Breast Cancer, Carbohydrate Engorgement, Proliferation, Insulin Resistance
- Trial name
- BCDIS (NCT03886389)
- Testing
- PreOP
- Volunteers
- 80 people
- Sponsor
- Helse Stavanger HF
Breast Cancer, Sentinel Lymph Node
Pain Control for Breast Cancer Patients Receiving Injection of Radioactive Tracer
The purpose of this study is to compare the effectiveness four different pain treatments for the injection of radioactive tracer that women with breast cancer receive for sentinel lymph node biopsies.
- Conditions
- Breast Cancer, Sentinel Lymph Node, Breast Neoplasms, Breast Cancer Female
- Trial name
- NCT04822597
- Testing
- Lidocaine patch, Buzzy(R), Ice pack
- Where
- United States
- Volunteers
- 167 people
- Sponsor
- University of Wisconsin, Madison
Gastric Cancer, Triple Negative Breast Cancer
A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
This is a a Multicenter, Open-label, Single-arm, Phase Ib Dose Escalation and Multi-cohort Expansion Clinical Study to Assess the Safety and Antitumor Activity of Niraparib in Combination with MGD013 in Patients with Advanced or…
- Conditions
- Gastric Cancer, Triple Negative Breast Cancer, Biliary Tract Carcinoma, Endometrial Carcinoma
- Trial name
- NCT04178460
- Testing
- Niraparib combined with MGD013
- Where
- 19 sites in China
- Volunteers
- 60 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Metastatic Breast Cancer, Locally Advanced Breast Cancer
Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy
The aim of the present study is to evaluate the efficacy and safety of palbociclib plus fulvestrant after failure of a combined treatment of hormonal therapy (aromatase inhibitor or tamoxifen ± LHRHa) plus a CDK4/6 inhibitor, in…
- Trial name
- NCT04318223
- Testing
- Palbociclib
- Where
- 19 sites in Italy
- Volunteers
- 168 people
- Sponsor
- Consorzio Oncotech
Breast Cancer
Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer
Dose dense therapy has been shown to increase survival in the adjuvant setting of breast cancer. It is unknown if dose dense therapy will improve survival in tumors that express her-2.
- Trial name
- NCT00232479
- Testing
- trastuzumab, docetaxel and carboplatin in dose dense regimen
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Miami
Breast Cancer, Colon Cancer
EXoPERT EMERALD Clinical Study
The purpose of this study is to establish a multi-center clinical repository of blood samples to support the development and evaluation of an artificial intelligence-based in vitro diagnostic software.
- Conditions
- Breast Cancer, Colon Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- NCT07186296
- Testing
- EXoPred
- Where
- 9 sites in United States
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- EXoPERT
Triple Negative Metastatic Breast Cancer
Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer
Patients with triple negative metastatic breast cancer (HER2-, PR-, ER-) will receive bevacizumab, paclitaxel and capecitabine as a first line of treatment (possibility to have received adjuvant chemotherapy).
- Trial name
- NCT01069796
- Testing
- Paclitaxel, Bevacizumab, Capecitabine
- Where
- 17 sites in France
- Volunteers
- 64 people
- Sponsor
- ARCAGY/ GINECO GROUP
Primary Breast Cancer
Large Language Model-Based Emotional Management for Breast Cancer Patients
This study (study type: randomized controlled trial) aims to evaluate whether a large language model-based precision emotional management intervention can improve health-related quality of life among patients with primary breast…
- Trial name
- EMBRACE (NCT07452055)
- Testing
- Large Language Model-Based precision emotional intervention system, Usual Care Group
- Where
- China
- Volunteers
- 440 people
- Sponsor
- Nanfang Hospital, Southern Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.